SCHEMBL16748426

SCHEMBL16748426

Cc1nc2ccc(F)cc2n1-c1nc(N)nc(Nc2ccc(Cl)c(F)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 4/20 0.44
DHFR P00374 5/20 0.43
MAPK1 P28482 1/20 0.38
TERT O14746 1/20 0.38
CYBB P04839 1/20 0.38
NOX5 Q96PH1 1/20 0.38
NOX3 Q9HBY0 1/20 0.38
NOX4 Q9NPH5 1/20 0.38
NOX1 Q9Y5S8 1/20 0.38
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
MTOR P42345 1/20 0.37
PIK3CG P48736 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.37
MAP3K14 Q99558 1/20 0.36
APP P05067 1/20 0.36
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748419 0.89 PIK3CA (0.45) BMI1DHFRPIK3CDPIK3CAPIK3CB
SCHEMBL16748613 0.89 BMI1 (0.48) BMI1DHFRMAP3K14
SCHEMBL16748427 0.87 MAPK1 (0.38) DHFRMAPK1TERTCYBBNOX5
SCHEMBL16748445 0.86 BMI1 (0.50) BMI1DHFRMAPK1TERTCYBB
SCHEMBL16550106 0.85 BMI1 (0.52) BMI1DHFRAURKAAURKBRAPGEF4
SCHEMBL15747537 0.85 BMI1 (0.41) BMI1DHFRRAPGEF4MAP3K14
SCHEMBL16748437 0.84 BMI1 (0.48) BMI1DHFRTERTCYBBNOX5
SCHEMBL15742368 0.84 BMI1 (0.42) BMI1DHFRRAPGEF4MAP3K14
SCHEMBL16748532 0.84 BMI1 (0.51) BMI1DHFRTERTCYBBNOX5
SCHEMBL16748533 0.82 BMI1 (0.64) BMI1DHFRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885DHFR 4017/4885MAPK1 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.